Cargando…

On Chip Immuno-Affinity Profiling of Cancer- and Benign Hyperplasia-Associated Free Prostate Specific Antigen

Prostate specific antigen (PSA) exhibits pronounced heterogeneity in both primary structure and glycan composition, resulting in the existence of different molecular forms. Investigation of PSA structure is a demanding task facing limitations due to inadequate sensitivity of analytical techniques an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosanovic, Maja M., Goc, Sanja R., Potpara, Goran S., Jankovic, Miroslava M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826388/
https://www.ncbi.nlm.nih.gov/pubmed/21897005
http://dx.doi.org/10.3233/DMA-2011-0809
_version_ 1782290906818281472
author Kosanovic, Maja M.
Goc, Sanja R.
Potpara, Goran S.
Jankovic, Miroslava M.
author_facet Kosanovic, Maja M.
Goc, Sanja R.
Potpara, Goran S.
Jankovic, Miroslava M.
author_sort Kosanovic, Maja M.
collection PubMed
description Prostate specific antigen (PSA) exhibits pronounced heterogeneity in both primary structure and glycan composition, resulting in the existence of different molecular forms. Investigation of PSA structure is a demanding task facing limitations due to inadequate sensitivity of analytical techniques and low concentrations of the different forms. This study aimed to profile free PSA (fPSA), especially lower molecular mass species lacking detailed classification, in normal seminal plasma and in sera from subjects with benign hyperplasia (BPH) or cancer of the prostate (PCa) as samples of known clinical relevance. fPSA forms were separated from complex proteomes on chips with immobilized anti-fPSA antibody followed by detection using surface-enhanced laser desorption/ionization time of flight mass spectrometry. At least 39 fPSA-immunoreactive species, ranging from 3–29 kDa were detected in seminal plasma. General fPSA profiles in seminal plasma and sera were similar, but differed in the abundance and presence of particular peaks/clusters of the lower molecular mass species. No striking difference in fPSA forms was observed between BPH and PCa samples, but some distinct peaks varied in intensity and frequency within or between groups. Obtained data verify fPSA heterogeneity that might be important for better exploration of all their molecular and marker potentials.
format Online
Article
Text
id pubmed-3826388
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-38263882013-12-01 On Chip Immuno-Affinity Profiling of Cancer- and Benign Hyperplasia-Associated Free Prostate Specific Antigen Kosanovic, Maja M. Goc, Sanja R. Potpara, Goran S. Jankovic, Miroslava M. Dis Markers Other Prostate specific antigen (PSA) exhibits pronounced heterogeneity in both primary structure and glycan composition, resulting in the existence of different molecular forms. Investigation of PSA structure is a demanding task facing limitations due to inadequate sensitivity of analytical techniques and low concentrations of the different forms. This study aimed to profile free PSA (fPSA), especially lower molecular mass species lacking detailed classification, in normal seminal plasma and in sera from subjects with benign hyperplasia (BPH) or cancer of the prostate (PCa) as samples of known clinical relevance. fPSA forms were separated from complex proteomes on chips with immobilized anti-fPSA antibody followed by detection using surface-enhanced laser desorption/ionization time of flight mass spectrometry. At least 39 fPSA-immunoreactive species, ranging from 3–29 kDa were detected in seminal plasma. General fPSA profiles in seminal plasma and sera were similar, but differed in the abundance and presence of particular peaks/clusters of the lower molecular mass species. No striking difference in fPSA forms was observed between BPH and PCa samples, but some distinct peaks varied in intensity and frequency within or between groups. Obtained data verify fPSA heterogeneity that might be important for better exploration of all their molecular and marker potentials. IOS Press 2011 2011-09-06 /pmc/articles/PMC3826388/ /pubmed/21897005 http://dx.doi.org/10.3233/DMA-2011-0809 Text en Copyright © 2011 Hindawi Publishing Corporation.
spellingShingle Other
Kosanovic, Maja M.
Goc, Sanja R.
Potpara, Goran S.
Jankovic, Miroslava M.
On Chip Immuno-Affinity Profiling of Cancer- and Benign Hyperplasia-Associated Free Prostate Specific Antigen
title On Chip Immuno-Affinity Profiling of Cancer- and Benign Hyperplasia-Associated Free Prostate Specific Antigen
title_full On Chip Immuno-Affinity Profiling of Cancer- and Benign Hyperplasia-Associated Free Prostate Specific Antigen
title_fullStr On Chip Immuno-Affinity Profiling of Cancer- and Benign Hyperplasia-Associated Free Prostate Specific Antigen
title_full_unstemmed On Chip Immuno-Affinity Profiling of Cancer- and Benign Hyperplasia-Associated Free Prostate Specific Antigen
title_short On Chip Immuno-Affinity Profiling of Cancer- and Benign Hyperplasia-Associated Free Prostate Specific Antigen
title_sort on chip immuno-affinity profiling of cancer- and benign hyperplasia-associated free prostate specific antigen
topic Other
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826388/
https://www.ncbi.nlm.nih.gov/pubmed/21897005
http://dx.doi.org/10.3233/DMA-2011-0809
work_keys_str_mv AT kosanovicmajam onchipimmunoaffinityprofilingofcancerandbenignhyperplasiaassociatedfreeprostatespecificantigen
AT gocsanjar onchipimmunoaffinityprofilingofcancerandbenignhyperplasiaassociatedfreeprostatespecificantigen
AT potparagorans onchipimmunoaffinityprofilingofcancerandbenignhyperplasiaassociatedfreeprostatespecificantigen
AT jankovicmiroslavam onchipimmunoaffinityprofilingofcancerandbenignhyperplasiaassociatedfreeprostatespecificantigen